The combination product space is critical to drug delivery innovation and compliant delivery can be the most important factor for successful uptake of a medicine.At IIR’s 18th Annual Drug Delivery Partnerships in Boca Raton, FL on January 27-29, there is a full-day symposium on "Developing Combination Device and Drug Products!"
Led by industry innovators from 11 different companies including Abbvie, Biogen, and MedImmune , this workshop addresses technical hurdles, regulatory complexities, and case studies for the development of combination device and drug products across the delivery continuum of biologics to small molecules and across the technology spectrum of injectables to alternate delivery systems.
Here are just samples of sessions from the Developing Combination Device and Drug Products symposia:
Implications for the New FDA Regulations on Combination Products for the Creation of Device Quality Management Systems and Complaint Reporting Systems for MDRs lead by Robert Walsh, Contract Medical Director, Pharmacovigilance and Safety, Abbvie
The Importance of Considering All Aspects of an Integrated Delivery System to Help Optimize Patient Outcomes lead by Graham Reynolds, Vice President, Marketing and Innovation, Pharmaceutical Delivery Systems, West Pharmaceutical Services
Injection Time Prediction for Early Drug Delivery System Design Definition and Improved Patient Experience lead by Paul Roussel, Sr Scientist, Process Biochemistry, Drug Delivery & Devices, MedImmune Fabien Dubuc, R&D Staff Engineer, BD Medical - Pharmaceutical Systems, Self-Administration Injection Systems
To learn more, download the agenda.
Use priority code XP1978BLOG to register and save $100 off of the current rate. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.
Cheers,
The Drug Delivery Partnerships International Team
Opt-in for updates
Follow us on Twitter
Join our LinkedIn Group
No comments:
Post a Comment